Calliditas Therapeutics AB Extraordinary Meeting Announcement
Announcement of Extraordinary Meeting of Calliditas Therapeutics AB
The shareholders of Calliditas Therapeutics AB (publ) are invited to an extraordinary general meeting to discuss crucial company matters. The meeting will take place at the offices of Advokatfirman Vinge in an upcoming session, confirming our commitment to transparency and shareholder engagement.
Background of the Meeting
Recently, Asahi Kasei Corporation has made a public offer which was accepted, granting them ownership of over 90% of Calliditas Therapeutics shares. Asahi Kasei has requested this extraordinary meeting to discuss important agenda items. They will propose resolutions regarding matters listed in agenda items 7-11 during the meeting.
Participation Rights for Shareholders
Eligible shareholders wishing to attend must be recorded in the share register by a specific date. Notification of participation needs to be submitted by mail or email, providing personal details and the number of accompanying assistants. If attending by proxy, written authorization must be provided.
Nominee-Registered Shares
For shareholders with nominee-registered shares, they must ensure their shares are registered in their own name to attend. This can be done temporarily through a voting rights registration request.
Share Information
As of now, there are 54,033,447 ordinary shares eligible for voting, coupled with 5,908,018 shares held by the company itself which do not entitle to vote at the meeting. This amounts to 59,941,465 shares, of which only the 54,033,447 shares will be represented during the meeting.
Agenda for the Meeting
- Opening of the meeting
- Election of a chairman of the meeting
- Preparation and approval of the voting register
- Approval of the meeting agenda
- Election of one or two persons to approve the meeting minutes
- Confirmation of proper meeting convening
- Determination of the board members count
- Election and removal of board members as needed
- Setting of board member fees
- Decision on the nomination committee principles post delisting
- Resolution on group management remuneration guidelines after delisting
- Closing remarks of the meeting
Election of Meeting Chairman
The nomination committee has recommended Dain Hård Nevonen as the chairman for this general meeting, allowing for a structured and effective session.
Shareholder Information Rights
During the meeting, shareholders are entitled to pose inquiries to the board of directors and the CEO. Questions can be submitted in advance either via post or by email to ensure their inclusion during discussions.
Additional Information for Attendees
Proxy forms are accessible at the company’s headquarters and also downloadable from the corporate website. It's advisable to procure these forms well in advance to ensure smooth registration at the meeting.
Data Protection Practices
For details surrounding the handling of personal data, shareholders can refer to the privacy policy available on the Euroclear website, emphasizing our commitment to protecting personal information.
Conclusion of Meeting Notice
We encourage all shareholders to be present at this significant event in shaping Calliditas Therapeutics AB’s future direction and governance. The board looks forward to engaging with shareholders during this meeting.
Frequently Asked Questions
What is the purpose of the extraordinary meeting?
The meeting aims to discuss important agenda items in light of recent ownership changes and corporate governance adjustments.
How can shareholders participate in the meeting?
Shareholders must register their participation and, if necessary, ensure their nominations are aligned correctly to vote.
Who will lead the extraordinary meeting?
Dain Hård Nevonen will be elected as the chairman to oversee the proceedings.
Can shareholders ask questions during the meeting?
Yes, shareholders have the right to ask questions and obtain information related to the discussions and decisions made during the meeting.
Where can I find more information about the meeting?
Further details, including the agenda and notes, will be available on the company's website and at their headquarters ahead of the meeting date.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Altamira Therapeutics Attends H.C. Wainwright Conference 2024
- Sustainable Apparel Market Projected to Hit USD 24.53 Billion
- GeoVax Labs, Inc. Announces Upcoming Investor Events!
- National Police Association Opposes New Liability Insurance Bill
- Outlook Therapeutics to Present at Major Investment Conference
- Avenue Therapeutics Announces Participation in Investor Conferences
- Y-mAbs Therapeutics to Present at Key Investor Conferences
- Cemat A/S Announcements of Managerial Transactions
- Schwab Insights: Boost Your Retirement Savings Effectively
- Keros Therapeutics Progresses in Phase 2 TROPOS Trial for PAH
- Protara Therapeutics to Showcase Innovations at H.C. Wainwright Conference
- LAVA Therapeutics Prepares for H.C. Wainwright Conference 2024
- Compass Therapeutics Engages Investors at Upcoming Events
- Denali Therapeutics Plans Accelerated Approval for DNL310
- Pasithea Therapeutics Welcomes Dr. Rebecca Brown to Advisory Board
- Bicara Therapeutics Pursues IPO for Innovative Cancer Treatments
- Forward Therapeutics Appoints Ulrich Thienel as CMO
- Earnings Reports Tuesday: Zscaler, Gitlab, Healthequity Insights
- DSV A/S Launches Major Share Buyback Program Announcement
- NRx Pharmaceuticals and HOPE Therapeutics to Present at Conference
- US Stock Futures Drop as Labor Data Week Begins
- Amicus Therapeutics to Showcase at Investor Conferences This Fall
- Elevai Labs Inc. Unveils Promising Hair Restoration Data
- Abeona Therapeutics Engages Investors at Upcoming Conferences
- Altimmune Unveils Pemvidutide Clinical Data at Diabetes Meeting
Recent Articles
- Nord Anglia Education Celebrates Student I/GCSE Success
- Lake City Bank Enhances Warsaw Campus with New Center
- Alto Ingredients, Inc. to Present at H.C. Wainwright Conference
- Worksport's Dealer Initiative Drives Strong Sales Growth
- 4DMT Engages at 2024 Cantor Global Healthcare Conference
- Green Bonds Market Expected to Reach $960 Billion by 2033
- Tourmaline Bio Announces Participation in Investor Conferences
- Arbutus Biopharma's Upcoming Conferences and Innovations
- Digital Health Market Estimates Growth to $1,924.95 Billion
- Ensign Group Expands Reach with Seven New Facilities in Colorado
- Symbotic Inc. Investors Alert: Class Action Lawsuit Notice
- Bitcoin's Recent Surge: Economic Data and Fed Decisions Ahead
- Investing in the Future: AI Stocks to Consider Now
- Plastic Pigments Market Projected to Reach $22.5 Billion by 2032
- Industrial 3D Printing Market Projected to Reach $88 Billion
- System Integration Market Set for 13.5% Growth by 2033
- 21.co Launches Wrapped Bitcoin (21BTC) on Ethereum
- GN Store Nord Share Transactions by Executives Unveiled
- Warren Buffett's Top Pick: Why Berkshire Hathaway Stands Out
- 5G Chipsets Market Growth Projected to Exceed $132 Billion
- Citi Analysts See Bullish Sentiment Waning in US Equities
- Valmet Sets Schedule for Financial Reporting in 2025
- Aker BP Launches Oil Production from Tyrving Field
- AMSilk Joins the World Economic Forum's Global Innovators Community
- Volt Lithium Announces Annual General Meeting Date and Changes